Similar articles for PMID: 25202034

Year	Number of Results
2002	2
2003	1
2004	1
2006	2
2009	3
2010	5
2011	2
2012	6
2013	11
2014	12
2015	33
2016	29
2017	39
2018	35
2019	28
2020	21
2021	15
2022	14
2023	2
2024	0

1

Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.

Covvey JR, Mancl EE. Covvey JR, et al. Ann Pharmacother. 2014 Dec;48(12):1611-9. doi: 10.1177/1060028014551015. Epub 2014 Sep 8. Ann Pharmacother. 2014. PMID: 25202034 Review.

2

Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Rogliani P, et al. Pulm Pharmacol Ther. 2016 Oct;40:95-103. doi: 10.1016/j.pupt.2016.07.009. Epub 2016 Jul 29. Pulm Pharmacol Ther. 2016. PMID: 27481628 Review.

3

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.

Rochwerg B, Neupane B, Zhang Y, Garcia CC, Raghu G, Richeldi L, Brozek J, Beyene J, Schünemann H. Rochwerg B, et al. BMC Med. 2016 Feb 3;14:18. doi: 10.1186/s12916-016-0558-x. BMC Med. 2016. PMID: 26843176 Free PMC article.

4

Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.

Canestaro WJ, Forrester SH, Raghu G, Ho L, Devine BE. Canestaro WJ, et al. Chest. 2016 Mar;149(3):756-66. doi: 10.1016/j.chest.2015.11.013. Epub 2016 Jan 13. Chest. 2016. PMID: 26836914 Review.

5

Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.

Fleetwood K, McCool R, Glanville J, Edwards SC, Gsteiger S, Daigl M, Fisher M. Fleetwood K, et al. J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S5-S16. doi: 10.18553/jmcp.2017.23.3-b.s5. J Manag Care Spec Pharm. 2017. PMID: 28287346 Free PMC article. Review.

6

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.

Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. Rinciog C, et al. Pharmacoeconomics. 2017 Apr;35(4):479-491. doi: 10.1007/s40273-016-0480-2. Pharmacoeconomics. 2017. PMID: 28039616 Free PMC article.

7

Nintedanib for the treatment of idiopathic pulmonary fibrosis.

Varone F, Sgalla G, Iovene B, Bruni T, Richeldi L. Varone F, et al. Expert Opin Pharmacother. 2018 Feb;19(2):167-175. doi: 10.1080/14656566.2018.1425681. Epub 2018 Jan 12. Expert Opin Pharmacother. 2018. PMID: 29327616 Review.

8

The evolving pharmacotherapy of pulmonary fibrosis.

Lota HK, Wells AU. Lota HK, et al. Expert Opin Pharmacother. 2013 Jan;14(1):79-89. doi: 10.1517/14656566.2013.758250. Expert Opin Pharmacother. 2013. PMID: 23265249 Review.

9

Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.

Wongkarnjana A, Yanagihara T, Kolb MR. Wongkarnjana A, et al. Expert Rev Respir Med. 2019 Dec;13(12):1139-1146. doi: 10.1080/17476348.2019.1673733. Epub 2019 Oct 9. Expert Rev Respir Med. 2019. PMID: 31564185 Review.

10

Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.

Potts J, Yogaratnam D. Potts J, et al. Ann Pharmacother. 2013 Mar;47(3):361-7. doi: 10.1345/aph.1R337. Epub 2013 Feb 12. Ann Pharmacother. 2013. PMID: 23404802 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

245 results

Results by year